<DOC>
	<DOCNO>NCT02936817</DOCNO>
	<brief_summary>Primary : The primary objective study evaluate effect Aerobika® device aerosol deposition pattern concomitant inhalation medication use FRI . Secondary : The secondary objective study evaluate effect Aerobika® device airway volume ( iVaw ) , lung lobe volume ( iVlobes ) , airway resistance ( iRaw ) , hyperinflation , airway wall thickness ( iVaww ) , blood vessel density ( iVbv ) , air trap use FRI .</brief_summary>
	<brief_title>Study Assess Effect Aerobika Device Addition Standard Care Treatment Sputum Producing COPD Patients Using FRI</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>1 . Male female subject ≥ 40 ≤ 85 year old . 2 . Written inform consent obtain . 3 . Subject documented diagnosis COPD GOLD II IV severity accord GOLD guideline , 4 . Subject cooperative attitude ability train correctly use Aerobika® device . 5 . Female subject childbearing potential must confirm contraception method use least 14 day Visit 1 continue use contraception method study . 6 . Subject must sputum produce treated accordance GOLD guideline . Sputum produce subject define patient report productive cough sputum `` several day week '' ( &gt; 2 day week ) `` almost every day '' month prior study . 7 . Subject must able understand complete protocol requirement , instruction protocolstated restriction . 8 . Subject must use standard care treatment . The regime standard care treatment must stable dose medication least 1 week Visit 1 . 9 . Subject unchanged smoking status within 3 month Visit 1 throughout study period . 1 . Pregnant lactate female . 2 . Subject upper low airway infection resolve within 4 week Screening Visit . 3 . Subject experience exacerbation define acute change patient 's baseline dyspnea , cough , and/or sputum beyond normal day day variation necessitate administration double systemic corticosteroid treatment within 4 week Screening Visit . 4 . Subjects unable tolerate increase work breathing . 5 . Subject history cerebrovascular disease 6 . Patient clinical significant hemodynamic instability ( i.e . blood pressure instability ) . 7 . Subject recent facial , oral , skull surgery trauma . 8 . Subject active acute sinusitis . 9 . Subject active epistaxis ( i.e . bleed nose ) . 10 . Subject history esophageal surgery . 11 . Subject active diagnosis nausea Visit 1 . 12 . Subject active hemoptysis ( i.e . bleed lung ) . 13 . Subject untreated pneumothorax ( i.e . untreated collapsed lung ) . 14 . Subject know suspected tympanic membrane rupture middle ear pathology . 15 . Subject unable perform pulmonary function test . 16 . Subject uncontrolled disease condition might , judgement investigator , place patient undue risk potentially compromise result interpretation study . 17 . Subject active cancer chronic disease poor prognosis /or affect patient status 18 . Subject unlikely comply protocol unable understand nature , scope , possible consequence study . 19 . Subject receive investigational new drug within 4 week Visit 1 twice duration biological effect drug ( whichever longer ) . 20 . Subject history alcohol substance abuse , opinion investigator , may clinical significance . 21 . Subject undergone major surgery within 12 week Visit 1 plan undergo major surgery end study . 22 . Subject diagnosis asthma . 23 . Inability correctly use sham device .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>HRCT</keyword>
	<keyword>High Resolution Computed Tomography scan</keyword>
	<keyword>Functional Respiratory Imaging</keyword>
	<keyword>CT scan</keyword>
	<keyword>Computed Tomography</keyword>
	<keyword>COPD</keyword>
	<keyword>sputum produce COPD patient</keyword>
	<keyword>Aerobika® device</keyword>
</DOC>